In a nutshell This study examined the safety and effectiveness of rituximab (Rituxan) to treat relapsed or unresponsive chronic lymphocytic leukemia (CLL) in a real-world setting. Authors concluded that rituximab was safe and effective in these patients. Some background Chronic lymphocytic leukemia is a cancer of the immune system. It...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Evaluating BEAM conditioning for allogeneic stem cell transplantation in patients with relapsed or unresponsive lymphoma
In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...
Read MoreEvaluating the long-term outcomes of Zevalin for patients with advanced B cell lymphoma
In a nutshell This study evaluated the long-term outcomes of patients with advanced (stage 3 – 4) non-Hodgkin’s lymphoma (NHL) who received radioimmunotherapy before allogeneic stem cell transplantation (alloSCT). This study concluded that this treatment regimen improved survival in most of these patients. Some background AlloSCT involves...
Read MoreVenetoclax-rituximab combination improves survival in patients with unresponsive and relapsed chronic lymphocytic leukemia
In a nutshell This study looked at the effectiveness of venetoclax-rituximab (Venclexta–Rituxan) in patients with unresponsive or relapsed chronic lymphocytic leukemia (CLL). Researchers found that this treatment improved survival in patients with CLL. Some background Chronic lymphocytic leukemia is a cancer of the bone marrow. This can...
Read MoreManagement of patients with unresponsive diffuse large B cell lymphoma
In a nutshell This study reviewed recent recommendations in the management of patients with diffuse large B cell lymphoma (DLBCL). Some background DLBCL is the most common type of non-Hodgkin lymphoma (NHL). The current standard treatment includes chemotherapy and immunotherapy such as R-CHOP (rituximab, cyclophosphamide, doxorubicin,...
Read MoreInotuzumab ozogamicin for children with unresponsive acute lymphoblastic leukemia
In a nutshell This study wanted to assess the safety and effectiveness of inotuzumab ozogamicin (InO; Besponsa) for the treatment of children with unresponsive acute lymphoblastic leukemia (ALL). Researchers found that InO was safe and effective in this group of patients. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone...
Read MoreEvaluating a new targeted therapy with or without itacitinib for relapsed or refractory lymphoma
In a nutshell This study evaluated the safety and effectiveness of a new targeted therapy (INCB040093) with or without itacitinib in patients with relapsed or refractory (does not respond to treatment) lymphoma. This study concluded that this new agent was well-tolerated and showed promising effectiveness in these patients. Some background...
Read MoreIs daratumumab added to lenalidomide plus dexamethasone better in multiple myeloma?
In a nutshell This article investigated the safety and effectiveness of adding daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the addition of daratumumab is safe and...
Read MoreEvaluating long-term outcomes of ibrutinib for relapsed or refractory mantle cell lymphoma
In a nutshell This study evaluated the long-term outcomes of ibrutinib (Imbruvica) treatment in patients with relapsed or refractory (does not respond to treatment) mantle cell lymphoma (MCL). This study concluded that ibrutinib is effective and well-tolerated in these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s...
Read MoreEvaluating resminostat for patients with relapsed or refractory Hodgkin’s lymphoma
In a nutshell This study evaluated the safety and effectiveness of resminostat in heavily pre-treated patients with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that resminostat was effective and well-tolerated in these patients. Some background Histone deacetylase inhibitors (HDIs)...
Read MoreThe safety and effectiveness of bosutinib in patients with chronic myeloid leukemia
In a nutshell This study looked at the safety and effectiveness of bosutinib (Bosulif) in the treatment of chronic myeloid leukemia (CML). Researchers found that bosutinib was effective in patients who have failed other similar drug treatments. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This can lead to abnormal...
Read MoreIs Daratumumab added to bortezomib plus dexamethasone better in treating multiple myeloma?
In a nutshell This article investigated the safety and effectiveness of adding daratumumab (Darzalex) to bortezomib (Velcade) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the addition of daratumumab is safe and gave the greatest benefit to...
Read More
